Vertex Pharmaceuticals Inc
VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Non-GAAP net income: $1,207M in Q2 2026, up 3.2% from a year earlier.
Latest, Q2 2026
1,207
Period ended Jun 30, 2026
Change on a year earlier
+3.2%
1,169 in Q2 2025
History
39 quarters
Since Q4 2016
Sources
34
Documents cited below
Where the Q2 2026 figure comes from
“|| Non-GAAP net income | $ | 1,207.3 | $ | 1,169.4 | $ | 2,354.3 | $ | 2,223.5”
Source: Form 8-K (ex-991_q22026.htm, filed 2026-08-03) ↗
Reported in Form 8-K EX-99.1 Earnings Releases (GAAP to Non-GAAP Reconciliations).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up non-GAAP net income
- Non-GAAP diluted earnings per share ($/sh)4.73 · Q2 2026
- Non-GAAP operating income ($M)1,423 · Q2 2026
- Non-GAAP combined R&D, AIPR&D and SG&A expenses ($M)1,430 · Q2 2026
- Non-GAAP cost of sales ($M)480 · Q2 2026
- Total pre-tax Non-GAAP adjustments (SBC, intangible amortization, contingent consideration & acquisition costs, $M)139 · Q2 2026
- Non-GAAP provision for income taxes ($M)324 · Q2 2026
- Non-GAAP total revenues (historical through FY2021, $M)2,073 · Q4 2021
Cite this data
StockData. (2026). Vertex Pharmaceuticals Non-GAAP net income ($M), quarterly Q4 2016–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/nongaap-netinc
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.